Real-world assessment of sparsentan’s drug safety framework

Sparsentan has been approved for reducing proteinuria in adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, yet comprehensive studies evaluating its drug safety framework are lacking. Adverse event (AE) reports following the market release of sparsentan were col...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Renal failure Ročník 47; číslo 1; s. 2461668
Hlavní autoři:	Fu, Wenjing, Wang, Jingyu, Xue, Yuzhou, Pan, Dikang
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Taylor & Francis Group 01.12.2025
Témata:	Adolescent Adult Adverse Drug Reaction Reporting Systems adverse events Angiotensin II Type 1 Receptor Blockers - adverse effects Clinical Trials, Phase III as Topic Endothelin A Receptor Antagonists - adverse effects FAERS Female Glomerulonephritis, IGA - drug therapy Humans IgA nephropathy Male pharmacovigilance Retrospective Studies sparsentan Young Adult FAERS IgA nephropathy adverse events sparsentan pharmacovigilance
ISSN:	0886-022X, 1525-6049, 1525-6049
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!